The role of vitamin D on the left ventricle ejection fraction in thalassemia major patients with cardiac hemosiderosis in Tabriz children’s hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150618022805N2

Enrollment

125

Registered

2018-04-28

Start date

2016-03-20

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major thalassemia. Beta thalassemia

Interventions

Vitamin D will be administered intramuscularly at a dosage of 50,000 units for the case group for 8 weeks..

Eligibility

Sex/Gender

All

Age

6 Months to No maximum

Inclusion criteria

Inclusion criteria: 1. Reduction of left ventricular ejection fraction by less than 55% based on echocardiography of the last three months 3. Treated with heart failure diagnosis by heart service 4. Level 25-Hydroxyvitamin D less than 30 ng / dl 5. Normal PTH serum levels 6. Serum magnesium levels are normal

Exclusion criteria

Exclusion criteria: 1. Exacerbation of heart failure 2. Occurrence of arrhythmias 3. Serum 25-Hydroxyvitamin D levels greater than 80 ng / dl 4. Severe constipation 5. Muscle weakness

Design outcomes

Secondary

Measure	Time frame
Constipation. Timepoint: During the administration period. Method of measurement: En Clinical Examination, Questionnaire.	—

Primary

Measure	Time frame
Vitamin D. Timepoint: Eevery 4 weeks. Method of measurement: Blood sample-questionnaire.;Heart hemosiderosis. Timepoint: Every 4 weeks. Method of measurement: Echocardiography-questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. amir ataloah hiradfar

Tabriz University of Medical Sciences

phrc_mb@tbzmed.ac.ir+98 41 3526 2265

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026